HLA-C and cancer: ImmTAC (immune-mobilizing monoclonal T-cell receptor against cancer) platform, developed by Immunocore, is composed of an engineered TCR that can recognize MHC-peptide complexes and is linked via a peptide linker to an anti-CD3 domain (made of scFv in tebentafusp).